Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
Analyst Insights: Goldman Sachs
Goldman Sachs said Friday that the second quarter of 2025 marked a key turning point for the company and reinforced its belief that Edwards is on track to achieve steady double-digit revenue growth again.
The firm noted that Edwards’ core TAVR business is gaining momentum, even though the quarter only partially reflected the impact of the new asymptomatic indication and included just a small boost from Boston Scientific Corporation’s (NYSE:BSX) planned market exit. This gives Goldman confidence that the business will operate at a stronger baseline.
Analyst David Roman expects Edwards to get back to its previous strong performance over the next few years, with revenue growing over 10% and operating margins above 30%. With this kind of growth, Goldman Sachs believes the stock deserves a higher valuation, more than 30 times its earnings. The analyst maintains the Buy rating, raising the price forecast from $89 to $101.
Other Analysts
Several leading financial analysts re-evaluated their outlook on Edwards Lifesciences, with a general trend toward increased price forecasts.
Baird has maintained a Neutral rating on the company, slightly increasing its price forecast from $78 to $79. Deutsche Bank, on the other hand, reiterates a Buy rating and has significantly raised its price forecast from $85 to $94.
Evercore ISI affirms an In-Line rating, with a modest increase in its price forecast from $77 to $80. Wells Fargo continues to maintain an Overweight rating, raising its price forecast from $80 to $84.
Similarly, RBC Capital maintains an Outperform rating, lifting its price forecast from $85 to $89. Piper Sandler also keeps an Overweight rating, increasing its price target from $83 to $90.
Barclays maintains an Overweight rating and has raised its price forecast from $90 to $95. Finally, a Stifel analyst has reiterated a Buy rating, also increasing the price forecast from $90 to $95.
Price Action: EW stock is trading higher by 4.87% to $79.49 at last check Friday.
Read Next:
Image via Shutterstock
Latest Ratings for EW
|
Date |
Firm |
Action |
From |
To |
|---|---|---|---|---|
|
Feb 2022 |
UBS |
Upgrades |
Neutral |
Buy |
|
Jan 2022 |
Morgan Stanley |
Maintains |
Overweight | |
|
Jan 2022 |
Raymond James |
Maintains |
Outperform |
View More Analyst Ratings for EW
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Content Original Link:
" target="_blank">
